Antimalarial prescribing under the National Health Insurance Scheme (NHIS)

Simple item page
dc.contributor.authorJoda, A.E.
dc.contributor.authorOlogunagba, M.O.
dc.date.accessioned2019-11-25T14:56:37Z
dc.date.available2019-11-25T14:56:37Z
dc.date.issued2014
dc.descriptionStaff publicationsen_US
dc.description.abstractBackground: Malaria is still a dreaded disease in many developing countries. Artemisinin-based Combination Therapy (ACT) was adopted for malaria control as it offers better efficacy to previous chloroquine-based remedies. The National Health Insurance Scheme (NHIS) was established to provide access to qualitative care at an affordable cost from different professional members of the healthcare team. Enrollees access care for approved health conditions in accredited facilities. Objectives: The objective was to document the antimalarial prescribing practices on prescriptions from NHIS-accredited medical facilities received in an NHIS-accredited community pharmacy in Lagos. Methods: A retrospective review of all the prescriptions received at the target NHIS-accredited pharmacy from four NHIS-accredited clinics over a 3-year period (2006-2008) was carried out using a modified WHO/INRUD prescribing indicator form. Data obtained was analyzed using descriptive and inferential statistics at p=0.05. Results were presented as frequency tables and charts. Results: About 51% of the prescriptions were for female patients. Over 60% of the prescriptions included an antimalarial. About 45% of the antimalarials prescribed was sulphadoxine/pyrimethamine (syrups and tablets). The use of ACTs increased over the 3-year period from about 9% to about 46% mainly as Artesunate plus a sulphadoxine-pyrimethamine product. Conclusion: Most of the antimalarial prescriptions did not comply with the antimalarial treatment policy of the country. Continuing Medical Education programs are required to improve prescriber knowledge and practice. Supervision of facilities by NHIS officials to ensure sustainability and good health outcome is recommended.en_US
dc.identifier.citationJoda, A.E and Ologunagba, MO. (2014). Antimalarial prescribing under the National Health Insurance Scheme (NHIS). West African Journal of Pharmacy, 25(1):97-105en_US
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/6965
dc.language.isoenen_US
dc.publisherWest African Journal of Pharmacyen_US
dc.relation.ispartofseriesWest African Journal of Pharmacy;Vol.25(1)
dc.subjectMalariaen_US
dc.subjectNHISen_US
dc.subjectHealth insuranceen_US
dc.subjectAntimalarial Prescriptionsen_US
dc.subjectTreatment guidelinesen_US
dc.subjectACTsen_US
dc.subjectContinuing educationen_US
dc.subjectResearch Subject Categories::PHARMACYen_US
dc.titleAntimalarial prescribing under the National Health Insurance Scheme (NHIS)en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
WAJP - 2014_25 - Antimalarial Prescribing under the NHIS Scheme.pdf
Size:
128.56 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Clinical Pharmacy and Biopharmacy- Scholarly Publications